Investment objective & strategy
As of July 29, 2025 · prospectusObjective. Macquarie Healthcare Fund seeks maximum long-term capital growth through capital appreciation.
Strategy. Under normal circumstances, Macquarie Healthcare Fund will invest at least 80% of its assets, plus the amount of any borrowings for investment purposes, in the equity securities of healthcare companies, meaning companies that develop, produce, or distribute products or services related to the healthcare or medical industries and derive a substantial portion, that is, more than 50%, of their sales from products and services in the healthcare industry (80% policy). These products and services include, but are not limited to, pharmaceutical companies, biotechnology companies, medical device and supply companies, managed care companies, and healthcare information and service providers. The Fund invests in US and non-US companies across all market capitalizations. The Fund may invest up to 50% of its total … Under normal circumstances, Macquarie Healthcare Fund will invest at least 80% of its assets, plus the amount of any borrowings for investment purposes, in the equity securities of healthcare companies, meaning companies that develop, produce, or distribute products or services related to the healthcare or medical industries and derive a substantial portion, that is, more than 50%, of their sales from products and services in the healthcare industry (80% policy). These products and services include, but are not limited to, pharmaceutical companies, biotechnology companies, medical device and supply companies, managed care companies, and healthcare information and service providers. The Fund invests in US and non-US companies across all market capitalizations. The Fund may invest up to 50% of its total assets in non-US companies. The Fund may also invest up to 25% of its total assets in companies located in emerging markets. The Fund is a nondiversified fund. The Manager may permit its affiliate, Macquarie Investment Management Global Limited (MIMGL), to execute Fund security trades on behalf of the Manager. The Manager may also seek quantitative support from MIMGL. The Funds 80% policy is nonfundamental and may be changed without shareholder approval. Fund shareholders would be given at least 60 days notice prior to any such change.
Top holdings
As of March 31, 2026 · N-PORT| Security | Ticker | Value | % of fund |
|---|---|---|---|
| UCB SA | — | $39.21M | 5.90% |
| REGENERON PHARMACEUTICALS INC | — | $36.31M | 5.46% |
| PFIZER INC | — | $32.15M | 4.84% |
| GILEAD SCIENCES INC | — | $29.27M | 4.40% |
| ABBVIE INC | — | $27.19M | 4.09% |
| MERCK & CO | — | $25.86M | 3.89% |
| ASTRAZENECA PLC | — | $25.66M | 3.86% |
| CHUGAI PHARMA CO | — | $24.82M | 3.73% |
| LILLY ELI and CO | — | $23.91M | 3.60% |
| ROCHE HOLDING AG | — | $21.95M | 3.30% |
Portfolio moves
Dec 31, 2025 → Mar 31, 2026How many positions this fund opened, exited, grew, trimmed, or left unchanged between its two most recent N-PORT snapshots — net changes between point-in-time reports, not a trade log.
Similar funds
Funds whose portfolios most overlap this one, by weight| Fund | Overlap | Net exp. |
|---|---|---|
| First Trust Nasdaq Pharmaceuticals ETF · FTXH | 40% | 0.60% |
| iShares Global Healthcare ETF · IXJ | 39% | 0.40% |
| Health Sciences Portfolio | 37% | 0.94% |
Advisers
| Firm | Role |
|---|---|
| Macquarie Investment Management Business Trust | Adviser |
| Macquarie Investment Management Global Limited | Sub-adviser |
Footnotes
- Expense ratio as of July 29, 2025, from the fund's prospectus.
- Net assets and holdings count as of March 31, 2026, from the fund's N-PORT filing.
- Total return for calendar year 2025, before tax and after fund expenses. Computed by compounding the twelve monthly total returns the fund reported in its SEC N-PORT filings for 2025 (the latest prospectus does not yet chart this year).
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.